China Duchenne Muscular Dystrophy (DMD) Therapeutics market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of 37.6% during the forecast period.
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness due to the alterations of a protein called dystrophin that helps keep muscle cells intact. Age of onset is usually between 3 and 5 years of age. The incidence of DMD is 1/4,709 in China and ranges from 1/3,802 to 1/6,291 in male births. There are around 60,000 DMD patients in China and these patients lack good treatment options.
China is a growing market for Duchenne muscular dystrophy (DMD) due to factor such as increase in incidence rate (1/4,709 in China and ranges from 1/3,802 to 1/6,291 in male births). Other factors that contribute to the growth of the market are awareness campaigns by various organizations, the growing necessity for advanced therapeutics and improved R&D activities.
However, there are some restraining factors for the growth of Duchenne muscular dystrophy (DMD) therapeutics market in China such as high cost of medicines and lack of insurance coverage for treatment.